Who we are
Infectious diseases such as human immunodeficiency virus (HIV), malaria, tuberculosis (TB), neglected and emerging infectious diseases remain a major cause of death, disability, and ill health in sub-Saharan Africa.
Established in 2021, the Global Health European and Developing Countries Clinical Trials Partnership 3 (Global Health EDCTP3) Joint Undertaking works deliver new solutions to reduce the burden of infectious diseases in sub-Saharan Africa and to strengthen research capacities to prepare and respond to re-emerging infectious diseases.
Consult our corporate brochure to learn more about our work.
To reduce the individual, social, and economic burden of poverty-related infectious diseases, including the neglected, emerging, and re-emerging infectious diseases, in sub-Saharan Africa.
To support global collaborative research, capacity strengthening, and international initiatives to accelerate the development, evaluation, and implementation of interventions to prevent, identify, and treat infectious diseases and emerging/re-emerging infections in sub-Saharan Africa with the overarching goal to reduce overall mortality and morbidity.
Global Health EDCTP3 will:
- contribute to the reduction of the socioeconomic burden of infectious diseases in sub-Saharan Africa by promoting the development and uptake of new or improved health technologies
- contribute to the increase of health security in sub-Saharan Africa and globally by strengthening the research- and innovation-based capacities for preparedness and response to control infectious diseases.